Novo Nordisk A/S Overview
Pro stress-test →Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a purpose to drive change to defeat serious chronic diseases built upon its heritage in diabetes. The company posted strong 2025 sales growth driven by obesity treatments and U.S. market performance, but faces a more cautious outlook for 2026 amid pricing pressure and intensifying competition.
Strategic Profile
Pro stress-test →Novo Nordisk researches, develops, manufactures, and distributes pharmaceutical products across two segments: Obesity and Diabetes Care, and Rare Disease. The company kicked off 2026 with its explosive obesity pill launch, but faces challenges in protecting market share in the blockbuster weight loss drug market. Around 246,000 patients are currently on Novo's Wegovy pill, which launched at the beginning of January and is already outpacing the early rollouts of existing GLP-1 injections.
Competitive Landscape
Pro stress-test →Novo faces intense competition from rival Eli Lilly, whose tirzepatide (Zepbound in obesity, Mounjaro in diabetes) became the world's best-selling medicine in 2025 and is projected to grow 23-27% in 2026 compared to Novo's expected decline. Novo is challenged by compounding pharmacies and cheaper compounded versions of semaglutide, which are unapproved copycats threatening its market position.
Industry Context
Novo Nordisk A/S operates in Pharmaceutical - Obesity & Diabetes Treatments.
Key facts
Founded: 1923 · Headquarters: Bagsvaerd, Denmark · Employees: 68,800 · Revenue: $46.7B (2025) · Market cap: $200B (approximate, as of Feb 2026)